

Express Mail No. EV 534 876 705 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Shiau et al.	Confirmation No.:	9894
Serial No.:	09/830,693	Art Unit:	1631
Filed:	March 30, 1999 (§ 371 date: January 29, 2002)	Examiner:	Nashed, Nashaat T.
For:	METHODS AND COMPOUNDS FOR MODULATING NUCLEAR RECEPTOR ACTIVITY	Attorney Docket No:	61040-0013-US

**PETITION FOR USE OF COLOR DRAWINGS
UNDER 37 CFR § 1.84(a)(2)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are three (3) sets color drawings, comprising FIGs. 1A, 1B, 2A, 2B, 3A–3D, 4A, 4B, 5A, 5B, and 6A–6D, for the above-referenced patent application.

In accordance with 37 C.F.R. § 1.84(a)(2), Applicants authorize the fee set forth in 37 C.F.R. § 1.17(h), as set forth below.

Also filed, on even date herewith, is an amendment and response under 37 C.F.R. § 1.111 that amends the specification of the subject patent application to include the specific reference to color drawings set forth in 37 C.F.R. § 1.84(a)(2).

Reason(s) for Petition

Applicants hereby request entry of color drawings into the file of the subject application for the following reason(s). Applicants' invention is connected with complicated three-dimensional structures of protein structures in which specific attributes of a ligand and coactivator binding sites, and binding interactions thereto, are described. In order for one of ordinary skill in the art to understand key features of the subject matter of the invention, it is necessary for color drawings to be included. Black and white drawings do not permit sufficient resolution — through shading or otherwise — to permit Applicants to effectively display characteristic features of the protein structure and interactions therewith. In

particular, certain secondary structural features of the binding sites must be clearly delineated, and overlaps of various molecules within the binding site must be clearly presented. Effective presentation of these features can only be accomplished by use of color drawings. Accordingly, it is respectfully requested that the instant petition be granted.

Applicants also request that, should it be deemed necessary to file at a later date a color version of FIG. 7, which also depicts receptor binding interactions, the instant petition, if granted, acts as pre-approval of such a filing.


Conclusion

Applicants have complied with the requirements of 37 C.F.R. § 1.84(a)(2) in connection with requesting approval for color drawings to be utilized in the subject patent application, and, accordingly, respectfully request approval of the instant petition that color drawings be accepted.

Please charge the required fee of \$130.00 under 37 C.F.R. § 1.17(h) to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310 (order no. 61040-0013). Should the Commissioner determine that this amount is incorrect, he is authorized to charge any underpayment, or credit any overpayment, to Deposit Account No. 50-0310. A copy of this sheet is enclosed.

Respectfully submitted,

Date: March 9, 2005



Richard G. A. Bone
Limited Recognition Under 37 C.F.R. § 11.9(b)
(Copy of Certificate attached hereto)

for Thomas D. Kohler, (Reg. No. 32,797)
MORGAN, LEWIS & BOCKIUS LLP
2 Palo Alto Square
3000 El Camino Real, Suite 700
Palo Alto, California 94306
(650) 843-4000



A.




FIG. 1A

B.




FIG. 1B




FIG. 2A-1




FIG. 2A-2




FIG. 2B-2




FIG. 2B-1

B.




FIG. 3A

FIG. 3B




FIG. 3C

FIG. 3D

A.




FIG. 4A

B.





FIG. 4B



A.





FIG. 6A




FIG. 6B





FIG. 6C



D.




FIG. 6D-1

FIG. 6D-2